var title_f4_8_4224="Clinical characteristics XDR TB";
var content_f4_8_4224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Modifiable and non-modifiable clinical characteristics of XDR-TB patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 465px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CXR: chest radiograph; AFB: acid fast bacilli; ART: antiretroviral therapy; ALP: alkaline phosphatase.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Shenoi SV, Brooks RP, Barbour R, et al. \"Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa.\" PLoS ONE 2012 7:e31786. Copyright &copy; 2012 The Public Library of Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4224=[""].join("\n");
var outline_f4_8_4224=null;
var title_f4_8_4225="Circumscribed morphea - inflammatory plaque";
var content_f4_8_4225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumscribed morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An indurated plaque with central hypopigmentation and peripheral erythema is present in this patient with circumscribed morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4225=[""].join("\n");
var outline_f4_8_4225=null;
var title_f4_8_4226="Types of lice";
var content_f4_8_4226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of lice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three varieties of lice specifically parasitic for humans are Phthirus pubis (picture A, crab louse), Pediculosis humanus capitis (picture B, head louse), and Pediculosis humanus corporis (picture C, body louse).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4226=[""].join("\n");
var outline_f4_8_4226=null;
var title_f4_8_4227="Patient information: Sickle cell anemia (The Basics)";
var content_f4_8_4227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/40/34433\">",
"         Patient information: Priapism (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/25/39318\">",
"         Patient information: Adult vaccines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/18/37156\">",
"         Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sickle cell anemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sickle-cell-anemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11333208\">",
"      <span class=\"h1\">",
"       What is sickle cell anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sickle cell anemia, also called sickle cell disease, is a condition that affects the red blood cells. The red blood cells are the part of the blood that carries oxygen to organs in the body. Normal red blood cells are round.",
"     </p>",
"     <p>",
"      When people have sickle cell anemia, their red blood cells have an abnormal shape. They look like a crescent (or an old-time tool called a &ldquo;sickle&rdquo;). The abnormal red blood cells get stuck in the blood vessels easily, and so they don&rsquo;t bring enough oxygen to the body&rsquo;s organs.",
"     </p>",
"     <p>",
"      Sickle cell anemia is a life-long condition that people are born with. It is caused by an abnormal gene. To get the disease, people need to get the abnormal gene from both their mother and father. If people get the abnormal gene from only 1 parent, it&rsquo;s called &ldquo;sickle cell trait.&rdquo; People with sickle cell trait do not usually have any of the symptoms of sickle cell anemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333223\">",
"      <span class=\"h1\">",
"       What are the symptoms of sickle cell anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms usually start after a baby is a few months old. Most commonly, people with sickle cell anemia have episodes of pain (also known as a sickle cell &ldquo;crisis.&rdquo;) The pain is usually in the bones of the back, chest, belly, arms, or legs. It can be mild or severe, and last hours to days. People can have other symptoms with their pain, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Swelling (for example, in the hands or feet)",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Often, certain things cause the pain. These things can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Infection",
"       </li>",
"       <li>",
"        Dehydration &ndash; Dehydration is when the body loses too much water.",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"       <li>",
"        High-altitude places &ndash; These are places where there is less oxygen in the air, such as mountains.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sickle cell anemia can also cause many different health problems, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Anemia &ndash; Anemia is a condition in which the body has too few red blood cells. It makes people tired or weak.",
"       </li>",
"       <li>",
"        Getting a lot of infections",
"       </li>",
"       <li>",
"        Strokes &ndash; A stroke is when a part of the brain dies.",
"       </li>",
"       <li>",
"        Open sores on the skin (usually on the legs)",
"       </li>",
"       <li>",
"        An erection that lasts too long and is very painful (in men)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333238\">",
"      <span class=\"h1\">",
"       Is there a test for sickle cell anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A blood test can show if someone has sickle cell anemia. All newborn babies (in the US) are tested for sickle cell anemia before they leave the hospital.",
"     </p>",
"     <p>",
"      Some parents choose to test their unborn baby for sickle cell anemia. This can be done in different ways.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333253\">",
"      <span class=\"h1\">",
"       How is sickle cell anemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sickle cell anemia involves life-long treatment. Some treatments help prevent infections, pain, and other problems. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; Daily antibiotics help prevent infections in young children.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?28/61/29653?source=see_link\">",
"         Hydroxyurea",
"        </a>",
"        (sample brand names: Droxia, Hydrea) &ndash; This medicine helps prevent episodes of pain.",
"       </li>",
"       <li>",
"        Blood transfusions &ndash; A blood transfusion is when a person gets blood that was given by another person. People who have a high chance of having a stroke might get blood transfusions to help prevent strokes. People might also get blood transfusions to treat anemia.",
"       </li>",
"       <li>",
"        A vitamin called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        (also called folate)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with sickle cell anemia are also treated for:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Their pain &ndash; Doctors can use different medicines to treat pain. If the pain is severe, people might need treatment in the hospital.",
"       </li>",
"       <li>",
"        Any other problems caused by the disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A procedure called a &ldquo;bone marrow transplant&rdquo; can cure sickle cell anemia. This procedure replaces the cells in the bone marrow (the inside part of bones) with healthy cells. But this treatment is not done very often for sickle cell anemia. That&rsquo;s because it can be done only if people meet certain conditions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333268\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call the doctor or nurse right away if the person with sickle cell anemia:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gets a fever or infection",
"       </li>",
"       <li>",
"        Has pain that doesn&rsquo;t get better after it is treated at home",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333283\">",
"      <span class=\"h1\">",
"       What else can people with sickle cell anemia do to stay healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with sickle cell anemia should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        See their doctor for regular check-ups, and follow his or her instructions about treatments and tests.",
"       </li>",
"       <li>",
"        Get the vaccines that the doctor or nurse recommends. Vaccines are treatments that can prevent certain serious infections.",
"       </li>",
"       <li>",
"        Avoid getting dehydrated, stressed, or being in high-altitude places.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333298\">",
"      <span class=\"h1\">",
"       What if I have sickle cell anemia and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have sickle cell anemia and want to get pregnant, talk with your doctor or nurse. He or she might recommend that you see a &ldquo;genetic counselor.&rdquo; This person can tell you your baby&rsquo;s chance of having sickle cell anemia or sickle cell trait.",
"     </p>",
"     <p>",
"      If you have sickle cell anemia and are pregnant, your doctor will follow you and your baby closely throughout your pregnancy. That&rsquo;s because sickle cell anemia can cause problems for both you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11333313\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=see_link\">",
"       Patient information: Priapism (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       Patient information: Adult vaccines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/8/4227?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16730 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4227=[""].join("\n");
var outline_f4_8_4227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333208\">",
"      What is sickle cell anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333223\">",
"      What are the symptoms of sickle cell anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333238\">",
"      Is there a test for sickle cell anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333253\">",
"      How is sickle cell anemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333268\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333283\">",
"      What else can people with sickle cell anemia do to stay healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333298\">",
"      What if I have sickle cell anemia and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11333313\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/40/34433?source=related_link\">",
"      Patient information: Priapism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4228="Scopolamine (ophthalmic): Patient drug information";
var content_f4_8_4228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Scopolamine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/58/24484?source=see_link\">",
"     see \"Scopolamine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/56/9092?source=see_link\">",
"     see \"Scopolamine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9522576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Hyoscine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an eye exam.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to scopolamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12302 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4228=[""].join("\n");
var outline_f4_8_4228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024577\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024576\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024581\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024582\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024584\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024579\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024580\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024585\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024586\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/58/24484?source=related_link\">",
"      Scopolamine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/56/9092?source=related_link\">",
"      Scopolamine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32375?source=related_link\">",
"      Scopolamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/12/10437?source=related_link\">",
"      Scopolamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/0/39941?source=related_link\">",
"      Scopolamine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4229="Advanced sarcoidosis PA";
var content_f4_8_4229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long standing sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest radiograph shows interstitial opacities with upper zone predominance, volume loss, and advanced fibrosis (Stage IV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4229=[""].join("\n");
var outline_f4_8_4229=null;
var title_f4_8_4230="Estradiol and dienogest: Patient drug information";
var content_f4_8_4230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estradiol and dienogest: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/14/22759?source=see_link\">",
"     see \"Estradiol and dienogest: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10192348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Natazia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10436198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10436226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heavy bleeding during monthly periods (menstruation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10436186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2821539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estradiol, dienogest, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10436188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10436539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10436190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10436246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2821580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not miss a dose by more than 12 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your monthly cycle is 28 days and you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10436187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2821639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been less than 12 hours since a normal dose, take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10436604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10436191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15574 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6001DE224-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4230=[""].join("\n");
var outline_f4_8_4230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10192348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436198\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436226\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436186\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436188\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436539\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436190\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436246\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436187\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436604\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10436191\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/14/22759?source=related_link\">",
"      Estradiol and dienogest: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4231="Role of cytokines in the immune system";
var content_f4_8_4231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of cytokines in the immune system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4231/contributors\">",
"     Iain B McInnes, FRCP, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4231/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4231/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4231/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/8/4231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune system is a complex network designed to protect the host from both external (such as bacteria and viruses) and internal threats (such as malignant transformation). Cytokines are important mediators of immune responses.",
"   </p>",
"   <p>",
"    Cytokine-directed treatments are being developed by the pharmaceutical and biotechnology industry as therapeutic agents for a number of autoimmune diseases. Clinicians using these treatments should understand the role of cytokines in the normal immune system, a topic that is reviewed here. The role of cytokines in the pathogenesis and treatment of rheumatic disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF IMMUNE RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune system is organized into innate and adaptive immune responses, with adaptive immunity further subdivided into two branches, humoral and cell mediated immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Innate immunity is immediate and rapid. Innate defense mechanisms include neutrophils and macrophages, which, among other functions, can ingest and destroy pathogens. While often effective in protecting the host, innate immunity is associated with damage to host tissue in the context of providing defense. It is also amnestic in that the inciting agent is not specifically recognized by a unique structure. In addition, there is no creation of a memory to that agent such that future responses are more efficient.",
"   </p>",
"   <p>",
"    Adaptive immunity is slower in its response to threats. However, it provides two main features that innate immunity lacks: specific antigen recognition and memory that allows rapid recall of original antigen exposure. Host defense is generally provided in two major arms of the adaptive response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Humoral immunity, which relies upon the production of antibodies by B cells and plasma cells.",
"     </li>",
"     <li>",
"      Cell mediated immunity, which involves the interactions of helper and cytotoxic T cells with various target cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immune cells produce a variety of products that allow them to communicate with each other and orchestrate an explosive, yet self-limited attack. Cytokines, in particular, are potent glycoprotein mediators that have the following properties:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They signal between cells and coordinate the immune response (ie, they are the hormones of the immune system)",
"     </li>",
"     <li>",
"      They are delivered by cells either to the systemic circulation or to the local environment",
"     </li>",
"     <li>",
"      They bind to high affinity surface receptors",
"     </li>",
"     <li>",
"      They are also produced by nonimmune cells (fibroblasts, endothelial cells)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines are hormone-like proteins that enable immune cells to communicate, and play an integral role in the initiation, perpetuation, and subsequent downregulation of the immune response. The nomenclature for cytokines is rather confusing for historical reasons, and it is useful to review the various names that have been used. The term",
"    <strong>",
"     lymphokine",
"    </strong>",
"    was coined to describe cytokines derived from lymphocytes, while",
"    <strong>",
"     monokines",
"    </strong>",
"    were produced by monocytes or macrophages. Unfortunately, these distinctions were quite artificial and rapidly broke down because some cytokines are produced by many cell types, including macrophages, lymphocytes, fibroblasts, and endothelial cells. Furthermore, some \"monokines\" are expressed by lymphocytes and some \"lymphokines\" are made by monocytes. In order to eliminate this confusion, the general term",
"    <strong>",
"     cytokine",
"    </strong>",
"    was introduced to identify this class of mediators (",
"    <a class=\"graphic graphic_table graphicRef69910 \" href=\"UTD.htm?15/12/15565\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another area of confusion arose from the fact that many cytokines were simultaneously discovered by more than one group based upon different biologic activities. Often, these laboratories then named the factors based upon their activities, resulting in a situation in which a single molecule might have several different names. As an example, interleukin-6 (IL-6) was originally identified as a factor that enhanced B cell antibody production, acted as a hybridoma growth factor, and functioned as a modulator of acute phase reactants. As a result, names like B cell stimulating factor (BSF) or hybridoma growth factor (HGF) could refer to the same molecule.",
"   </p>",
"   <p>",
"    The term interleukin (or IL) has greatly improved the nomenclature. Once a factor has been sufficiently characterized, it receives an interleukin designation (such as IL-2 or IL-6). It is clear, however, that even this can be misleading, since cells besides leukocytes are capable of producing interleukins.",
"   </p>",
"   <p>",
"    Despite the introduction of these general designations, some cytokines are still denoted by their descriptive names. For instance, colony stimulating factors (CSF) were originally described as proteins that stimulate the growth and differentiation of bone marrow precursors into mature hematopoietic or myeloid cells. We now know that CSFs also have potent immunoregulatory functions and can activate macrophages, neutrophils, and T cells. Similarly, interferons (IFN) (alpha, beta and gamma), tumor necrosis factor (TNF) (alpha and beta), platelet derived growth factor (PDGF), fibroblast growth factor (FGF) (acidic and basic) and many molecules have not received an IL designation, even though their descriptive names usually represent only one of many activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CYTOKINE INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cells can communicate with one another by either direct contact or through the secretion of soluble mediators. Direct cell-cell contact regulates immune function of adjacent cells by a variety of mechanisms, including membrane bound cytokines like TNF-alpha. In contrast, release of soluble mediators into the environment permits cells to exert influence at a distant site within the tissue. In some cases, cytokines can even reach distant cells in other organs via the peripheral circulation. For instance, IL-6 produced at a local inflammatory site can enhance liver acute phase protein production. Soluble cytokines bind to a specific receptor on the surface of target cells and transduce a signal that alters cellular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CYTOKINE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines are most commonly measured in their soluble form, but they can also be measured in the tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Soluble cytokine assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokine interactions that are mediated by direct contact are difficult to quantify; as a result, this aspect of cytokine biology has not been studied extensively in vivo. In contrast, soluble cytokines have been measured in various body fluids and tissues, and these measurements provide a window into the pathogenesis of the inflammatory process. Determinations of soluble cytokine levels typically use two types of assays: biologic and immunologic assays (",
"    <a class=\"graphic graphic_table graphicRef56208 \" href=\"UTD.htm?6/59/7099\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Biologic assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biologic assay is often the most sensitive test for a particular cytokine. This type of assay generally involves examining the effect of a test sample on a cell line. Proliferation, antibody production, or changes in the surface phenotype are examples of responses that can be measured after a cell has been exposed to a cytokine. Despite their sensitivity, bioassays often suffer from a lack of specificity and can be difficult to perform. As an example, biologic assays designed to measure proliferation of a particular cell line in response to one cytokine might also proliferate in response to a different cytokine. Also, inhibitors of cytokine activity, such as prostaglandins, soluble receptors, or natural antagonists, can also interfere with these assays. As a result, biologic assays are of limited utility when studying complex biologic samples containing a mixture of biologically active entities of similar function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Immunoassay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokine concentrations can also be determined using immunoassays, which employ antibodies to capture and detect a specific cytokine. There are many techniques that can be used, but the most common method is the \"sandwich\" assay (enzyme linked immunosorbent assay or ELISA). In this system, a sample is added to a microtiter well that has been coated with an antibody. The antibody binds the cytokine and a second anticytokine antibody that is linked to an indicator is subsequently added. The amount of the second antibody that binds to the \"captured\" protein is proportional to the concentration of the cytokine in the original sample. The absolute amount of cytokine can then be calculated using a standard curve derived by adding known amounts of recombinant cytokine. This method has been considerably advanced by attaching capture antibodies to beads that are detectable by fluorescent activated cell sorters and therefore amenable to the measurement of multiple cytokines within small samples (eg, approximately 20 cytokines can be measured in 50 microliters). This modification is termed multiplex analysis.",
"   </p>",
"   <p>",
"    Immunoassays are often simpler and more reproducible than biologic assays, although antibody cross-reactivity can lead to false positive results. In addition, false positives or negatives can be caused by rheumatoid factors, especially in autoimmune diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Artifacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other artifacts can interfere with cytokine assays of biologic fluids. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cytokines can be degraded by proteases or absorbed by receptors on activated cells",
"     </li>",
"     <li>",
"      Soluble receptors in the sample that bind cytokines can interfere with biologic activity or block epitopes recognized by antibodies",
"     </li>",
"     <li>",
"      Cytokines can also be absorbed by matrix proteins, such as glycosaminoglycans and thereby be undetected using standard assays",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these problems, cytokine assays of complex fluids (such as synovial effusions) should always be interpreted with caution. These issues have also led many investigators to analyze cytokine expression at the mRNA level, which can be more reliable, but is arduous. An additional caveat is that protein and mRNA production do not always correlate. A full understanding of the cytokine profile typically requires the use of multiple different assay systems to avoid these pitfalls. In parallel, other protein-based and proteomic approaches are being increasingly employed. As an example, cytokines may now be detected using western blotting, although this technique is not yet quantitative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Localizing cytokines in tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best method for localizing cytokines in tissues is examining the protein level by immunohistochemistry. Specific antibodies bind to cytokines in permeabilized tissue sections. Bound antibody is detected using a second antibody that recognizes the first antibody (ie, secondary anti-Ig antibody). The second antibody is most often directly labeled with a fluorescent chemical (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    isothiocyanate, FITC) to allow detection and localization by immune fluorescent microscopy. Using a variety of antibodies and fluorescent colors allows double and even triple staining of cells to co-localize cellular expression of cytokines in vivo.",
"   </p>",
"   <p>",
"    Alternatively, the secondary antibody may be bound to a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    molecule, which allows an additional layer of detection using streptavidin-FITC, or streptavidin-enzyme (eg, alkaline phosphatase). The choice of enzyme allows addition of a further substrate, which changes color upon exposure to the enzyme. This color change can be localized on a tissue by light microscopy.",
"   </p>",
"   <p>",
"    Cytokines can also be quantified at the mRNA level. RNA can be purified from tissue biopsies and assayed by traditional reverse transcription polymerase chain reaction (RT-PCR), in which results are obtained at the end of the reaction, or real-time PCR, which measures kinetics of the PCR reaction in the early phases. Localization in tissue may also be performed using in situ hybridization, which detects the presence of the cytokine mRNA in tissue using an anti-sense sequence of nucleotides that are labeled to allow detection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CYTOKINES IN NORMAL IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed description of the role of cytokines in normal immunity is beyond the scope of this topic review. A brief summary of this subject is needed, however, in order to understand how cytokines or their antagonists ultimately might be used in clinical situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antigen presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen presentation is initiated when an antigen is recognized and processed by an antigen presenting cell (APC). The most potent APCs are macrophages and dendritic cells, but a diverse collection of cells possess this capacity, including B cells and Langerhans cells. Antigen processing is a carefully orchestrated series of events that involves antigen internalization, degradation into small polypeptides, and then reexpression of the peptide on the surface of the cell bound to major histocompatibility proteins, such as HLA-DR. The antigen can then be presented to T cells that express the appropriate T cell receptor for the specific antigen.",
"   </p>",
"   <p>",
"    The T",
"    <span class=\"nowrap\">",
"     cell/APC",
"    </span>",
"    complex also involves a number of accessory molecules (CD4 or CD8, CD3, and intercellular adhesion molecule-1) and costimulatory proteins (eg, B7 and CD28, ICOS, PD-1) (",
"    <a class=\"graphic graphic_figure graphicRef78712 \" href=\"UTD.htm?13/22/13668\">",
"     figure 1",
"    </a>",
"    ). These molecules serve to stabilize interactions between the two cells and enhance or suppress subsequent T cell activation.",
"   </p>",
"   <p>",
"    The ensuing stimulation of T cells by antigen and APCs depends upon the elaboration of cytokines. The precise cytokines elaborated have a critical influence on the nature of the subsequent T cell response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     T cell subsets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytokine profile subsequently produced depends upon the type of antigen, the local cytokine milieu, and the prevalence of specific T cell subsets. Distinct helper T cell subsets have been identified (especially in mice) by virtue of cytokines that they produce. These subsets appear to modulate specific aspects of immunity (",
"    <a class=\"graphic graphic_figure graphicRef78712 \" href=\"UTD.htm?13/22/13668\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Th1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th1 cells produce IFN-gamma and IL-2, but not IL-4. Th1 cells regulate delayed-type hypersensitivity reactions. Th1 responses are promoted by local release of the IL-12 superfamily of cytokines including IL-27, IL-23, and IL-12. IL-12 may favor IFN-gamma release whereas IL-23 may favor IL-17 release. These responses are further enhanced by IL-15 and IL-18 production by dendritic cells and macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Th2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th2 cells produce IL-4 and IL-10, but not IL-2 or IFN-gamma. Th2 cells mediate allergic and antibody responses. Th2 responses are favored by local production of IL-4, IL-33, and IL-18 in synergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Th17",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th17 cells are characterized by the production of IL-17A, together with a variety of other cytokines (IL-17F, IL-22, IL-26) and chemokines (CCL20). These cytokines are induced in the presence of IL-1beta, IL-6, IL-21, and possibly IL-23. To date, six isoforms, A-F, have been identified in the IL-17 family. IL-17A and IL-17F are expressed in activated Th17 cells and are upregulated during inflammatory processes. Th17 cells may play a role in a number of inflammatory diseases previously thought to be Th1 mediated.",
"   </p>",
"   <p>",
"    Some cytokines, such as IL-3, GM-CSF, and TNF-alpha, are produced by multiple Th subsets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Th0",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th0 cells have an unrestricted cytokine profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T regulatory (Treg) cells are a population of T cells with suppressive properties. Their cytokine dependence is unclear at this time. They are characterized by release of TGF-beta and IL-10, and possibly also IL-35, a novel member of the IL-12 superfamily. Their effector function is often dependent upon cell contact mediated cellular suppression.",
"   </p>",
"   <p>",
"    Aberrant immune responses in diseases like rheumatoid arthritis and asthma could be due, in part, to overactivity of Th1 or Th2 cells, respectively. Th17 cells probably also play a role in various inflammatory diseases, although their contribution in human disease is still being determined. The predominance of one T cell subset over another is determined by the cytokine milieu. As examples, the presence of IFN-gamma or IL-12 favors Th1 development while IL-10 and IL-4 promote Th2 cell dominance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, T cells do not appear to segregate quite as cleanly into these subsets, and there are many other cytokine combinations that have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/5\">",
"     5",
"    </a>",
"    ]. However, general patterns of Th1, Th2, Th17, and Th0 cells have been identified and probably play a role in the human immune response, including the susceptibility to develop autoimmune disease or various forms of T-cell and B-cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Amplification effects of cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant cytokine or cytokines further amplifies the response through positive feedback loops. Activities can include recruitment of inflammatory cells, inhibition of cell migration, enhancement of T cell proliferation, enhancement of antigen expression, and stimulation of T cells or B cells.",
"   </p>",
"   <p>",
"    In general, Th1 responses result in cellular immune responses with localizing features (eg, formation of granulomata in tuberculous infection). The key effector cytokine is IFN-gamma, which promotes widespread leukocyte activation and organization together with activation of cytotoxic and phagocytic function.",
"   </p>",
"   <p>",
"    In contrast, Th2 responses lead to enhanced humoral immunity with antibody release; this is optimal for anti-viral responses and for defense against rapidly disseminated bacteria and parasites, or parasites in which mucosal immunity may be predominant. In Th2 dominant responses, IL-4 serves as the major T cell mitogen instead of IL-2 and suppresses differentiation of Th1 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/9\">",
"     9",
"    </a>",
"    ]. IL-13, which is very similar to IL-4 (their surface receptors share a common alpha subunit), can stimulate other Th2 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/10\">",
"     10",
"    </a>",
"    ]. IFN-gamma production is minimal, and Th1 activation is also suppressed by macrophage and Th2 cell derived IL-10. IL-5 is a further effector cytokine of Th2 responses. Activated CD4+ T cells interact with B cells, either directly or through soluble mediators like IL-2 or IL-4, and induce them to proliferate and differentiate into plasma cells that synthesize antibodies. Specific IgG subsets and IgE are predominant in Th2-mediated responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of Th17 cells in host defense is unclear, although some infectious processes seem dependent upon their activation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/12\">",
"     12",
"    </a>",
"    ]. These cells may be involved in the early response to extracellular bacteria and fungi. IL-21 amplifies Th17 proliferation. Further data are required to elucidate the role of Th17 in the immune response to pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cellular migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latter is accomplished by a highly redundant family of cytokines known as",
"    <strong>",
"     chemokines",
"    </strong>",
"    . These factors, including IL-8 and monocyte chemoattractant protein-1 (MCP-1), bind to specific surface receptors that induce cells to migrate into tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/13\">",
"     13",
"    </a>",
"    ]. Up to 40 chemokines are now described and their roles are very broad including not only induction of cellular migration, but also local cellular activation and survival. They are of increasing interest because their modulation in a variety of disease models suggests that they may represent therapeutic targets. Moreover their receptor structure predicts that small molecule inhibitors may be relatively easily generated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Negative feedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to positive feedback loops involving cytokines, many negative feedback signals down regulate the immune system. This prevents an inflammatory response from overwhelming and harming the host. A number of cytokines and small molecule mediators can dampen the immune response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostaglandins (such as prostaglandin E2) produced by macrophages can inhibit a variety of functions, including the induction of HLA-DR on macrophages and the production of IFN-gamma by T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transforming growth factor-beta (TGF-beta) is a potent suppressor of T cell activation and can decrease T cell proliferation and cytokine production [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/15\">",
"       15",
"      </a>",
"      ]. It also decreases the number of IL-1 receptors, thereby making cells less sensitive to other cytokines.",
"     </li>",
"     <li>",
"      IL-10 deactivates macrophages, which in turn decreases production of cytokines by T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-35 inhibits the amplification of Th17 cells, but not Th1 cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These control mechanisms are critical elements for keeping the inflammatory response in check and maintaining homeostasis. Their importance can be demonstrated in animals that lack some of these elements. As an example, rodents that lack the TGF-beta gene have a generalized inflammatory disease due to the absence of its suppressive influence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/18\">",
"     18",
"    </a>",
"    ]. This observation illustrates that cytokines are as important to the termination of the immune response as they are to its initiation. Their relationship to the role of Tregs is not entirely clear. The identification of the cytokines that regulate the production of regulatory T cells, both induced and native, will be of considerable importance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Effects beyond the immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A final area of developing interest resides in the recognition that cytokines interact with other physiologic systems including, for example, regulation of adipose tissue eg, via IL-6, adiponectin, resistin, leptin, or of hypothalamic pituitary function via IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4231/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15281035\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytokines are hormone-like proteins that enable immune cells to communicate. They play an integral role in the initiation, perpetuation, and subsequent downregulation of the immune response (",
"      <a class=\"graphic graphic_table graphicRef69910 \" href=\"UTD.htm?15/12/15565\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of immune responses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cells can communicate with one another by either direct contact or through the secretion of soluble mediators. Direct cell-cell contact regulates immune function of adjacent cells by a variety of mechanisms, including membrane bound cytokines. In contrast, soluble mediators permit cells to exert influence at a distant site within a tissue or even affect cells in other organs via the peripheral circulation or lymphatics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cytokine interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytokines are most commonly measured in their soluble form, but they can also be measured in the tissue (",
"      <a class=\"graphic graphic_table graphicRef56208 \" href=\"UTD.htm?6/59/7099\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antigen presentation is initiated when an antigen is recognized and processed by an antigen presenting cell (APC) (",
"      <a class=\"graphic graphic_figure graphicRef78712 \" href=\"UTD.htm?13/22/13668\">",
"       figure 1",
"      </a>",
"      ). The most potent APCs are macrophages and dendritic cells, but a diverse collection of cells possess this capacity, including B cells and Langerhans cells. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antigen presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD4+ T helper (Th) cells can be categorized by the profile of cytokines that they produce (",
"      <a class=\"graphic graphic_figure graphicRef78712 \" href=\"UTD.htm?13/22/13668\">",
"       figure 1",
"      </a>",
"      ). These subsets include Th0, Th1, Th2, Th17, and regulatory T cells. In general, Th1 responses result in cellular immune responses with localizing features. In contrast, Th2 responses lead to enhanced humoral immunity with antibody release. Th17 responses are increasingly recognized to play a role in a variety of autoimmune responses, but also to play a role in mucosal defence. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'T cell subsets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Amplification effects of cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an archetypal response, a predominant cytokine(s) amplifies the immune response through positive feedback loops. There are also negative feedback loops that downregulate the immune system. Normally, a given cytokine initiates an effector and a regulatory response to anticipate restoration of immune homeostasis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Amplification effects of cytokines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Negative feedback'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemokines bind to specific surface receptors that induce cells to migrate into tissues. They may also promote activation or other regulatory effects on target cells upon receptor binding. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Cellular migration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/1\">",
"      Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/2\">",
"      Firestein GS, Roeder WD, Laxer JA, et al. A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol 1989; 143:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/3\">",
"      Germann T, R&uuml;de E. Interleukin-12. Int Arch Allergy Immunol 1995; 108:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/4\">",
"      Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995; 103:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/5\">",
"      Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/6\">",
"      Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/7\">",
"      Arend WP. Cytokine inhibition in the treatment of rheumatic and inflammatory diseases. Jap J Rheumatol 1998; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/8\">",
"      Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/9\">",
"      Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/10\">",
"      de Vries JE, Zurawski G. Immunoregulatory properties of IL-13: its potential role in atopic disease. Int Arch Allergy Immunol 1995; 106:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/11\">",
"      Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995; 96:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/12\">",
"      Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/13\">",
"      Strieter RM, Koch AE, Antony VB, et al. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/14\">",
"      Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum 1987; 30:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/15\">",
"      Wahl SM, Allen JB, Wong HL, et al. Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium. J Immunol 1990; 145:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/16\">",
"      Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993; 11:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/17\">",
"      Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4231/abstract/18\">",
"      Diebold RJ, Eis MJ, Yin M, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci U S A 1995; 92:12215.",
"     </a>",
"    </li>",
"    <li>",
"     McInnes IB. Cytokines. In: Kelley's textbook of rheumatology, 7th ed, Harris E, Budd R, Firestein G, et al (Eds), Elsevier, London 2004.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3984 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-113.53.254.124-B894B13FA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4231=[""].join("\n");
var outline_f4_8_4231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15281035\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF IMMUNE RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CYTOKINE INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CYTOKINE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Soluble cytokine assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Biologic assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Immunoassay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Artifacts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Localizing cytokines in tissues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CYTOKINES IN NORMAL IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      T cell subsets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Th1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Th2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Th17",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Th0",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Amplification effects of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cellular migration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Negative feedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Effects beyond the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15281035\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3984|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/22/13668\" title=\"figure 1\">",
"      T cell regulation by cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/12/15565\" title=\"table 1\">",
"      Immune functions of cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/59/7099\" title=\"table 2\">",
"      Cytokine assays",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4232="Cases illustrating problems with intensive insulin therapy for diabetes mellitus";
var content_f4_8_4232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4232/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4232/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4232/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/8/4232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following cases illustrate some of the common problems that may arise during intensive insulin therapy in patients with type 1 diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LACK OF CONTROL DUE TO DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 57-year-old hospital administrator who has had type 1 diabetes for 15 years is trying very hard to maintain strict glycemic control. She keeps fit with exercise, and adjusts not only her insulin dose but also her food intake and exercise pattern in response to her blood glucose concentrations.",
"   </p>",
"   <p>",
"    Her usual insulin doses are:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 6 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 26 units NPH insulin",
"   </p>",
"   <p>",
"    &nbsp;Before lunch &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before bedtime &mdash; 26 units NPH insulin",
"   </p>",
"   <p>",
"    She is frustrated at the unpredictability of her blood glucose values, as shown below (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; evening meal &nbsp; &nbsp; &nbsp; &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;195 (10.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;52 (2.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;126 (7.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 88 (4.9)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;61 (3.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;46 (2.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;210 (11.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 197 (10.9)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;287 (15.9) &nbsp; &nbsp; &nbsp; &nbsp;222 (12.3) &nbsp; &nbsp; &nbsp; &nbsp;161 (8.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 72 (4.0)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;This patient is probably trying too hard. If a person continually adjusts insulin doses, food intake, and exercise, it is often impossible to identify patterns that can be corrected. In this woman, keeping a three-day food record can determine if there are major problems with dietary inconsistency (",
"    <a class=\"graphic graphic_figure graphicRef60634 \" href=\"UTD.htm?1/38/1646\">",
"     figure 1",
"    </a>",
"    ). As can be seen, the woman's total carbohydrate intake and its distribution are markedly different each day. This variability prevents the attainment of strict glycemic control with an intensive insulin regimen.",
"   </p>",
"   <p>",
"    You can attempt to correct the dietary inconsistency by advising her to consult a nutritionist or to attend a diet workshop, which can be set up for 6 to 10 patients at a time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4232/abstract/1\">",
"     1",
"    </a>",
"    ]. At these workshops, approximately 10 to 12 meals are laid out, including breakfasts, fast food lunches, fancy evening meals, and snacks. Patients are asked to estimate how many grams of carbohydrate are in each meal. Their (and clinicians') estimates are often remarkably",
"    <strong>",
"     inaccurate",
"    </strong>",
"    , but can improve with training. Once this has been achieved, it is then possible to develop a Consistent Carbohydrate Profile for each patient. The patient can quote this profile to you at every clinic visit and, more importantly, it becomes part of their conscious behavior at meal times. Rather than forcing a patient to eat the same amount of carbohydrate at the same meal every day with a fixed dose of insulin, some patients can be taught to calculate a carbohydrate:insulin ratio. As an example, this patient may need 1 unit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    to cover 15 g of carbohydrate. Although she typically eats 90 g of carbohydrate for breakfast (and so takes 6 units of regular insulin), if she ate only 30 g on one morning, she would reduce her regular insulin dose to 2 units. She might then use an insulin algorithm to adjust this basic dose based on her blood glucose concentration (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BEDTIME HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 27-year-old woman with type 1 diabetes is treated with the following regimen:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 8 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    and 20 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal &mdash; 4 units aspart",
"   </p>",
"   <p>",
"    &nbsp;Before bedtime &mdash; 12 units detemir",
"   </p>",
"   <p>",
"    Her blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are as follows:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; evening meal &nbsp; &nbsp; &nbsp; &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 86 (4.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;104 (5.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 96 (5.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;320 (17.8)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 146 (8.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;123 (6.8) &nbsp; &nbsp; &nbsp; &nbsp; 105 (5.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;296 (16.4)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 111 (6.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;97 (5.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 92 (5.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;341 (18.9)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main problem with her current level of glycemic control is hyperglycemia before bedtime. This can probably be improved by increasing the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    before her evening meal. It is also prudent to consider some other aspects of her lifestyle. As an example, she may be eating her evening meal very late, so that there is not much time between the meal and her bedtime test. Furthermore, the evening meal may be her biggest meal of the day. It would therefore be helpful to review her food record to see how she distributes her food and what type of food she is eating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MORNING HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-year-old insurance salesman with type 1 diabetes for two years feels stressed and tired at work and has early morning headaches. His hemoglobin A1C (A1C) value is 9.6 percent. Until fairly recently, he thought that his diabetes was well controlled. His current regimen is:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 6 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 28 units NPH insulin",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 16 units NPH insulin",
"   </p>",
"   <p>",
"    Blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;breakfast &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;snack &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; evening meal &nbsp; &nbsp; bedtime",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (8 AM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (12 PM) &nbsp; &nbsp; &nbsp; (1:30 PM) &nbsp; &nbsp; &nbsp; &nbsp;(5 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (11 PM)",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 282 (15.7) &nbsp; &nbsp; &nbsp;140 (7.8) &nbsp; &nbsp; 261 (14.5) &nbsp; &nbsp; &nbsp; 82 (4.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;130 (7.3)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 321 (17.8) &nbsp; &nbsp; &nbsp;163 (9.1) &nbsp; &nbsp; 294 (16.3) &nbsp; &nbsp; &nbsp; 96 (5.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;123 (6.8)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 280 (15.6) &nbsp; &nbsp; &nbsp;153 (8.5) &nbsp; &nbsp; 310 (17.2) &nbsp; &nbsp; 107 (5.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;144 (8.0)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing difficulty in maintaining glycemic control in this patient with recent-onset diabetes is probably due in part to a progressive decline in endogenous insulin secretion. In addition, his insulin regimen is not ideal &mdash; he is taking too little",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and too much NPH insulin. As an example, his high blood glucose values at 1:30 PM suggest that he needs to take regular insulin before lunch.",
"   </p>",
"   <p>",
"    On the other hand, the triad of reasonable blood glucose values before bedtime, very high fasting values before breakfast, and a history of tiredness and early morning headache suggest a problem with the NPH insulin dose that he is taking before his evening meal. The action of the NPH insulin may be maximal in the late evening and middle of the night (causing both normoglycemia at bedtime and",
"    <strong>",
"     nocturnal hypoglycemia",
"    </strong>",
"    ) and then dissipating in the early morning (causing",
"    <strong>",
"     hyperglycemia",
"    </strong>",
"    before breakfast) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis that nocturnal hypoglycemia leads to fatigue and decreased well-being was tested in a study of 10 patients with type 1 diabetes who were evaluated on the morning after experimentally-induced nocturnal hypoglycemia (for one hour at 41",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.3 mM]) and on a control night when hypoglycemia was avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4232/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptoms of well-being and fatigue were significantly worse after the night of hypoglycemia, although higher cerebral function was unchanged.",
"   </p>",
"   <p>",
"    The presence of nocturnal hypoglycemia followed by early morning hyperglycemia can be confirmed by measuring blood glucose at 3 AM. One solution is to move his evening dose of NPH insulin from before the evening meal to before bedtime. Another approach might be to switch from NPH insulin to an insulin with a longer, flatter profile (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or detemir). In addition, other aspects of his lifestyle should also be evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      He may not be eating enough carbohydrate in his evening meal or late night snack.",
"     </li>",
"     <li>",
"      Alternatively, the type of food he is eating may be inadequate to maintain his blood glucose concentration through the night. A bedtime snack that is low in protein, fat, and fiber may be entirely digested and absorbed within two or three hours.",
"     </li>",
"     <li>",
"      A review of his exercise patterns in the evening may also be helpful. Vigorous exercise at that time makes it more likely that his blood glucose concentration will fall to low values during the night.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following changes in his insulin regimen lead to marked improvement in his glycemic control:",
"   </p>",
"   <p>",
"    &nbsp;8 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=see_link\">",
"     insulin glulisine",
"    </a>",
"    and 30 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    before breakfast",
"   </p>",
"   <p>",
"    &nbsp;6 units glulisine before lunch",
"   </p>",
"   <p>",
"    &nbsp;8 units glulisine before the evening meal",
"   </p>",
"   <p>",
"    Three months later his blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; 3 AM",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;snack &nbsp; &nbsp; &nbsp; &nbsp; evening meal &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; 141 (7.7) &nbsp; &nbsp;110 (6.2) &nbsp; &nbsp;161 (8.9) &nbsp; &nbsp; 82 (4.6) &nbsp; &nbsp; &nbsp; &nbsp; 140 (7.8) &nbsp; &nbsp;92 (5.1)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; 121 (6.7) &nbsp; &nbsp;163 (9.1) &nbsp; &nbsp;134 (7.4) &nbsp; &nbsp; 96 (5.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;93 (5.2)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; 150 (8.3) &nbsp; &nbsp;153 (8.5) &nbsp; &nbsp;110 (6.2) &nbsp; &nbsp;107 (5.9) &nbsp; &nbsp; &nbsp; &nbsp;144 (8.0) &nbsp; 104 (5.9)",
"   </p>",
"   <p>",
"    His A1C value is now 7.8 percent. He has more energy, the headaches are gone, he is eating and exercising consistently, and has just been promoted because of his improved productivity. To reduce his A1C value to below 7.0 percent, he will probably require a pre-meal insulin algorithm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INSULIN ALGORITHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 43-year-old factory worker is striving for strict glycemic control with three injections of insulin per day. Her blood glucose concentrations are somewhat variable due to alterations in her food intake and exercise program. She is interested in using an insulin algorithm. Her current regimen consists of:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 8 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 15 units NPH insulin",
"   </p>",
"   <p>",
"    &nbsp;Before dinner &mdash; 7 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before bedtime &mdash; 8 units NPH insulin",
"   </p>",
"   <p>",
"    Her blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are as follows:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;breakfast &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; evening meal &nbsp; &nbsp; &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;159 (8.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 134 (7.4) &nbsp; &nbsp; &nbsp; &nbsp;186 (10.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;84 (4.7)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;117 (6.5) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 164 (9.1) &nbsp; &nbsp; &nbsp; &nbsp;210 (11.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;97 (5.4)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;102 (5.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 122 (6.8) &nbsp; &nbsp; &nbsp; &nbsp;261 (14.5) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;79 (4.4)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Her blood glucose concentrations vary before breakfast, lunch, and her evening meal (dinner). She should therefore adjust her doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    according to an insulin algorithm (",
"    <a class=\"graphic graphic_table graphicRef83951 \" href=\"UTD.htm?19/16/19723\">",
"     table 1",
"    </a>",
"    ). The algorithm is designed specifically for each patient. Different patients vary in how much the insulin doses need to be changed and what blood glucose values will be used to guide the changes. Some patients, as an example, need much smaller adjustments than others (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Late morning hyperglycemia'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    She should not take extra insulin before bedtime, and should not adjust her doses of NPH insulin.",
"   </p>",
"   <p>",
"    If this algorithm were applied to her current insulin regimen, then the alterations in her dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    on day 1 according to the blood glucose concentration would be:",
"   </p>",
"   <p>",
"    Day 1:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 159",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.8",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    add 1 unit",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    to total dose of 9 units",
"   </p>",
"   <p>",
"    &nbsp;Before lunch &mdash; 134",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.4",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    no insulin dose",
"   </p>",
"   <p>",
"    &nbsp;Before dinner &mdash; 186",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10.3",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    add 2U",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    to total dose of 9 units",
"   </p>",
"   <p>",
"    &nbsp;Before bedtime &mdash; 84",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.7",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    no change",
"   </p>",
"   <p>",
"    Similar adjustments would be made on subsequent days until glycemic control is attained. She could also consider using a carbohydrate:insulin ratio to allow her to take less food and less insulin at certain meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VARIABLE GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 32-year-old executive has a busy office job that is unpredictable in terms of physical activity, time of meals, or the length of the workday. Her current insulin regimen is:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 10 units NPH insulin",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal &mdash; 8 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and 14 units NPH insulin",
"   </p>",
"   <p>",
"    Her blood glucose records (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or, in parentheses, in",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for one week are as follows. The asterisk refers to hypoglycemic episodes and A refers to average values during the week.",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3 AM",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;evening meal &nbsp; &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;156 (8.7) &nbsp; &nbsp; &nbsp; 111 (6.2) &nbsp; &nbsp; &nbsp; 97 (5.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;63 (3.5)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;147 (8.2) &nbsp; &nbsp; &nbsp; &nbsp; 98 (5.4) &nbsp; &nbsp; &nbsp; 59* (3.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;301 (16.7)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;182 (10.1) &nbsp; &nbsp; 124 (7.9) &nbsp; &nbsp; &nbsp; 86 (4.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;87 (4.7) &nbsp; &nbsp; &nbsp; &nbsp;91 (5.1)",
"    <br/>",
"    4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;191 (10.6) &nbsp; &nbsp; 115 (6.4) &nbsp; &nbsp; &nbsp; 46* (2.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;62 (3.4)",
"    <br/>",
"    5 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;165 (9.3) &nbsp; &nbsp; &nbsp; 108 (6.0) &nbsp; &nbsp; 101 (5.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;235 (13.1)",
"    <br/>",
"    6 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;246 (13.7) &nbsp; &nbsp; &nbsp; 89 (4.9) &nbsp; &nbsp; &nbsp; 92 (5.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;57 (3.3) &nbsp; &nbsp; &nbsp; &nbsp;78 (4.3)",
"    <br/>",
"    7 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;178 (9.9) &nbsp; &nbsp; &nbsp; &nbsp; 97 (5.4) &nbsp; &nbsp; &nbsp; 67 (3.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;164 (9.1)",
"    <br/>",
"    A &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     181",
"    </strong>",
"    (10.1) &nbsp; &nbsp;",
"    <strong>",
"     106",
"    </strong>",
"    (5.9) &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     78",
"    </strong>",
"    (4.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     138",
"    </strong>",
"    (7.7)",
"   </p>",
"   <p>",
"    She played racquetball for one hour at 8 PM on day 4 and had a late night pizza at 11 PM on day 5.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of this patient's records can be best approached by considering each time period separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before breakfast &mdash; Her average blood glucose value before breakfast is too high at 181",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      The individual values are also fairly consistent (from 147 to 191",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [8.2 to 10.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      apart from one high value (246",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [13.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      on day 5, which can probably be explained by her late-night pizza the preceding day [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4232/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This patient should benefit from increasing her NPH insulin dose before the evening meal, since this is the insulin that is working during the night. However, her two 3 AM values are in the ideal range. There is therefore a risk that increasing her evening NPH insulin dose will induce nocturnal hypoglycemia. This risk can be minimized by increasing her evening NPH insulin in small increments and continuing to measure blood glucose both at 3 AM and before breakfast. Another approach is to have her take her evening dose of NPH insulin at bedtime, instead of before the evening meal. She could also be switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"       insulin detemir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Before lunch &mdash; Her before-lunch blood glucose values are consistent and average 106",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      This is very good control, suggesting that her morning dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      and her breakfast and mid-morning snacks are appropriate and consistent from day to day and that her exercise and work schedule for the morning are relatively constant. However, she may be in danger of hypoglycemia before lunch once her before breakfast glucose values are lowered as recommended above. It might therefore be wise to slightly decrease her morning regular insulin dose as the evening NPH insulin dose is increased.",
"     </li>",
"     <li>",
"      Before evening meal &mdash; Her before evening meal blood glucose values are too low, with an average value of 78",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and two hypoglycemic episodes during the week. These findings suggest that she may be taking too much NPH insulin before breakfast, since this is the insulin that is acting during the afternoon. Another possible explanation might be that her lunch is too early or too light, or that she doesn't eat an adequate mid-afternoon snack. There is inadequate information to identify the primary problem.",
"     </li>",
"     <li>",
"      Before bedtime &mdash; Her before bedtime blood glucose values average 138",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      While this average is close to ideal, the individual values vary widely from 57 to 301",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      This suggests that some variable aspect of her lifestyle is creating the fluctuations in the bedtime glucose values. Possible problems include variation in the time or content of her evening meal or in evening exercise. As an example, the blood glucose value of 301",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      before bedtime on day 2 may have resulted from dietary overcompensation for her hypoglycemic episode before the evening meal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, this patient's record keeping is better than most. Nevertheless, it is not sufficient to permit assessment of her problems before the evening meal and before bedtime. It would be helpful to know the exact times when her blood glucose was measured and exactly when she eats and the content of each meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LATE AFTERNOON HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 42-year-old garage mechanic is treated with the following insulin regimen:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast &mdash; 8 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    and 16 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before lunch &mdash; 4 units lispro",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal &mdash; 10 units lispro and 22 units glargine",
"   </p>",
"   <p>",
"    He uses an algorithm (",
"    <a class=\"graphic graphic_table graphicRef83953 \" href=\"UTD.htm?19/60/20427\">",
"     table 2",
"    </a>",
"    ) to adjust pre-meal doses of lispro insulin.",
"   </p>",
"   <p>",
"    Blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for one week are shown below. The doses of lispro (LP) and glargine (G) insulin are also noted. The asterisks on days 2 and 4 reflect hypoglycemic episodes.",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3 AM",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; &nbsp; &nbsp;lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;evening meal &nbsp; &nbsp; bedtime",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;100 (5.6) &nbsp; &nbsp; &nbsp; &nbsp;205 (11.4) &nbsp; &nbsp; 116 (6.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;115 (6.4)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 16 G &nbsp; &nbsp; &nbsp; 8 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 10 LP, 22 G",
"   </p>",
"   <p>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;118 (6.6) &nbsp; &nbsp; &nbsp; &nbsp;172 (9.6) &nbsp; &nbsp; &nbsp; 47* (2.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;124 (6.9) &nbsp; &nbsp; 92 (5.1)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 16 G &nbsp; &nbsp; &nbsp; 7 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 22 G",
"   </p>",
"   <p>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;77 (4.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;145 (8.1) &nbsp; &nbsp; &nbsp; &nbsp;85 (4.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 108 (6.0)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6 LP, 16 G &nbsp; &nbsp; &nbsp; 4 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 LP, 22 G",
"   </p>",
"   <p>",
"    4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;113 (6.3) &nbsp; &nbsp; &nbsp; &nbsp;136 (7.6) &nbsp; &nbsp; &nbsp; &nbsp;54* (3.0) &nbsp; &nbsp; &nbsp; &nbsp; 111 (6.2)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 16 G &nbsp; &nbsp; &nbsp; 5 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8 LP, 22 G",
"   </p>",
"   <p>",
"    5 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;132 (7.3) &nbsp; &nbsp; &nbsp; &nbsp; 97 (5.4) &nbsp; &nbsp; &nbsp; &nbsp;103 (5.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 97 (5.4) &nbsp; &nbsp; &nbsp;87 (4.8)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;9 LP, 16 G &nbsp; &nbsp; &nbsp; 4 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 LP, 22 G",
"   </p>",
"   <p>",
"    6 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;98 (5.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;122 (6.8) &nbsp; &nbsp; &nbsp; &nbsp;82 (4.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 102 (5.7)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 16 G &nbsp; &nbsp; &nbsp; 5 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 LP, 22 G",
"   </p>",
"   <p>",
"    7 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;158 (8.8) &nbsp; &nbsp; &nbsp; &nbsp;109 (6.1) &nbsp; &nbsp; &nbsp; &nbsp;93 (5.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;89 (4.9)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;8 LP, 16 G &nbsp; &nbsp; &nbsp; 4 LP &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 LP, 22 G",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;9:55 AM (late)",
"   </p>",
"   <p>",
"    A &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     114",
"    </strong>",
"    (6.3) &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     141",
"    </strong>",
"    (7.8) &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     83",
"    </strong>",
"    (4.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <strong>",
"     107",
"    </strong>",
"    (5.9)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;This patient's record is quite complete, but there is no information about the quantity of food eaten and periods of exercise. He is consistent about the timing of blood glucose testing and meals and has adjusted his insulin doses correctly using the algorithm. He made only one \"mistake.\" His blood glucose was measured between 7:05 and 7:15 AM every day except for day seven when he slept late and the test was done at 9:55 AM. According to the algorithm, he should have increased the dose of lispro insulin by 2U to 10U for a blood glucose value of 158",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Several other patterns can be detected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      He needed to take extra insulin before lunch on four of the seven days. This suggests that his pre-breakfast dose of lispro insulin may be too low or that his mid-morning snack is too large or taken too close to lunch.",
"     </li>",
"     <li>",
"      His average blood glucose value is",
"      <strong>",
"       too low",
"      </strong>",
"      (83",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      before the evening meal, with hypoglycemia occurring on days two and four. Possible explanations include a morning dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      or lunchtime dose of lispro insulin that is too high, or an inadequate midafternoon snack.",
"     </li>",
"     <li>",
"      His blood glucose values before bedtime and at 3 AM are normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LATE MORNING HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 21-year-old woman is 62 inches (157 cm) tall and weighs 104 lb (47 kg). She runs 40 miles per week. She is being treated with a continuous subcutaneous insulin infusion (CSII) according to the following insulin regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;Basal infusion rate &mdash; 0.4",
"    <span class=\"nowrap\">",
"     units/hour",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Pre-breakfast bolus dose &mdash; 3 units",
"   </p>",
"   <p>",
"    &nbsp;Pre-lunchtime bolus dose &mdash; 2 units",
"   </p>",
"   <p>",
"    &nbsp;Pre-evening meal bolus dose &mdash; 4 units",
"   </p>",
"   <p>",
"    She adjusts the pre-meal bolus doses according to the following algorithm (",
"    <a class=\"graphic graphic_table graphicRef83952 \" href=\"UTD.htm?19/21/19803\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    She has kept a three-day record of her glycemic control, with the doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    shown under the blood glucose values. The time of the pre-meal measurements is roughly constant from day to day.",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3 AM",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;evening meal &nbsp; &nbsp; bedtime",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    &nbsp; &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     (mmol/L)",
"    </span>",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;105 (5.7) &nbsp; &nbsp; &nbsp;195 (10.8) &nbsp; &nbsp; &nbsp;146 (8.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;125 (6.9)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3.5 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;5 units",
"   </p>",
"   <p>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;112 (6.2) &nbsp; &nbsp; &nbsp; 122 (6.8) &nbsp; &nbsp; &nbsp; 147 (8.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 94 (5.2) &nbsp; &nbsp; &nbsp;89 (4.9)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2.5 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 5 units",
"   </p>",
"   <p>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 77 (4.3) &nbsp; &nbsp; &nbsp; 186 (10.3) &nbsp; &nbsp; &nbsp;165 (9.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;108 (6.0)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3.5 units &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;5.5 units",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;This patient's records are complete with regard to time, blood glucose values, and insulin doses. She is consistent in terms of blood glucose testing and timing of meals, but we do not have information about the size and number of meals or the timing of exercise. This consistency is reflected in the relatively constant blood glucose levels at each time of day. She is appropriately increasing her before-lunch and before-evening meal bolus insulin doses, since her blood glucose values are elevated only at those times. The fact that she has to add insulin every day before lunch suggests that some adjustment may be needed in her overall regimen during the morning. She may need a larger pre-breakfast dose of insulin, a smaller breakfast or mid-morning snack, or an increase in her basal rate of insulin infusion. She could also consider using a carbohydrate:insulin ratio to allow her to take less food and less insulin at certain meals. It would also help if she switched from using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    in her pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVENING HYPERGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 34-year-old teacher is striving for excellent glycemic control. He eats a healthy diet, counts carbohydrates, exercises at a consistent time each day, and has been taking the following regimen:",
"   </p>",
"   <p>",
"    &nbsp;Before breakfast (6 AM) &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    and 14 units NPH",
"   </p>",
"   <p>",
"    &nbsp;Before lunch &mdash; 4 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp;Before evening meal (6 PM) &mdash; 6 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    and 14 units NPH insulin",
"   </p>",
"   <p>",
"    Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    are also adjusted using an insulin algorithm.",
"   </p>",
"   <p>",
"    Because of nocturnal hypoglycemia and unexplained variation in blood glucose concentrations before the evening meal, NPH insulin was stopped and replaced with a single dose of 28 units",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    taken at 10 PM. Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    remained the same. Typical blood glucose concentrations (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    a few weeks later are:",
"   </p>",
"   <p>",
"    Day &nbsp;Before breakfast &nbsp;Before lunch &nbsp;Before evening meal &nbsp;Before bed",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (6 AM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (11 AM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (6 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (10 PM)",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp;107 (5.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 123 (6.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 163 (9.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 296 (16.4)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp;130 (7.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 111 (6.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 146 (8.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 210 (11.7)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp;140 (7.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 144 (8.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 178 (9.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 261 (14.5)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose values are ideal before breakfast and lunch, but are somewhat high before the evening meal and are much too high before bedtime. Since he has not changed his eating habits or doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    , it is likely that the effect of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    is waning after 20 hours. He could try increasing the dose of insulin glargine or splitting it into two equal doses taken about 12 hours apart. Alternatively, he could increase the dose of insulin aspart before the evening meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SWITCHING FROM NPH INSULIN TO INSULIN DETEMIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 33-year-old man with type 1 diabetes is treated with the following regimen:",
"   </p>",
"   <p>",
"    Before breakfast &mdash; 28 units NPH insulin",
"   </p>",
"   <p>",
"    Before bedtime &mdash; 12 units NPH insulin",
"   </p>",
"   <p>",
"    He also administers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    by sliding scale before each meal.",
"   </p>",
"   <p>",
"    Despite being extremely consistent from day-to-day in his activity level and in the timing and carbohydrate content of his meals, he is having unpredictable swings in blood glucose concentrations with occasional episodes of hypoglycemia in the late morning or early afternoon.",
"   </p>",
"   <p>",
"    Blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are:",
"   </p>",
"   <p>",
"    Day &nbsp;Before breakfast &nbsp;Before lunch &nbsp;Before evening meal &nbsp;Before bed",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (8 AM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (12 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (5 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (11 PM)",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp;132 (7.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 54 (3.0)* &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 206 (11.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 118 (6.6)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp;119 (6.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 136 (7.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 140 (7.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 151 (8.4)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp;141 (7.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 108 (6.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 125 (6.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 107 (5.9)",
"    <br/>",
"    4 &nbsp; &nbsp; &nbsp;108 (6.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 48 (2.7)* &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 196 (10.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 140 (7.8)",
"   </p>",
"   <p>",
"    *Represent episodes of symptomatic hypoglycemia.",
"   </p>",
"   <p>",
"    In order to change from NPH to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    his total daily dose of NPH is calculated (28 + 12 = 40), decreased by 10 percent (4 units), and is given as a single injection of 36U of detemir insulin at bedtime.",
"   </p>",
"   <p>",
"    One week later his blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are:",
"   </p>",
"   <p>",
"    Day &nbsp;Before breakfast &nbsp;Before lunch &nbsp;Before evening meal &nbsp;Before bed",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (8 AM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (12 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (5 PM) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (11 PM)",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp;98 (5.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 124 (6.9)* &nbsp; &nbsp; &nbsp; &nbsp; 168 (9.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;213 (11.8)",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp;103 (5.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 131 (7.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 171 (9.5) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;232 (12.9)",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp;217 (12.1)* &nbsp; &nbsp; &nbsp; &nbsp; 127 (7.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 192 (10.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;251 (13.9)",
"    <br/>",
"    4 &nbsp; &nbsp; &nbsp;92 (5.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 119 (6.6)* &nbsp; &nbsp; &nbsp; &nbsp; 185 (10.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;211 (11.7)",
"   </p>",
"   <p>",
"    *He was awakened with hypoglycemia at 4 AM and took 60 grams of carbohydrate to treat this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Interpretation and approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;His blood glucose values before breakfast on days 1, 2 and 4 are slightly low. That, along with one episode of hypoglycemia at 4 AM, suggests that 36 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    may be too much for him. The blood glucose values before lunch are ideal, but they are too high before dinner and even higher before bedtime. This suggests that insulin detemir is not lasting 24 hours, but that its action wanes after 18 to 20 hours. After switching to 20 units insulin detemir twice daily (at about 8 AM and 8 PM) his blood glucose values became stable throughout the day.",
"   </p>",
"   <p>",
"    While many patients do well with a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    at bedtime, this case illustrates two practical points. Although its peak action is less than that of NPH insulin, it can have a slight peak in some patients which may result in hypoglycemia during the night [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4232/abstract/5\">",
"     5",
"    </a>",
"    ]. Also, although it lasts for 24 hours in some patients, some patients require two daily injections (",
"    <a class=\"graphic graphic_figure graphicRef64125 \" href=\"UTD.htm?35/61/36816\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4232/abstract/1\">",
"      McCulloch DK, Mitchell RD, Ambler J, Tattersall RB. Influence of imaginative teaching of diet on compliance and metabolic control in insulin dependent diabetes. Br Med J (Clin Res Ed) 1983; 287:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4232/abstract/2\">",
"      Gale EA, Tattersall RB. Unrecognised nocturnal hypoglycaemia in insulin-treated diabetics. Lancet 1979; 1:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4232/abstract/3\">",
"      King P, Kong MF, Parkin H, et al. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care 1998; 21:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4232/abstract/4\">",
"      Ahern JA, Gatcomb PM, Held NA, et al. Exaggerated hyperglycemia after a pizza meal in well-controlled diabetes. Diabetes Care 1993; 16:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4232/abstract/5\">",
"      Heise T, Nosek L, R&oslash;nn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1797 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4232=[""].join("\n");
var outline_f4_8_4232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LACK OF CONTROL DUE TO DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BEDTIME HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MORNING HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INSULIN ALGORITHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VARIABLE GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LATE AFTERNOON HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LATE MORNING HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVENING HYPERGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SWITCHING FROM NPH INSULIN TO INSULIN DETEMIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Interpretation and approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1797|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/38/1646\" title=\"figure 1\">",
"      Erratic CHO intake in IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/61/36816\" title=\"figure 2\">",
"      Pharmacokinetics insulin detemir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/16/19723\" title=\"table 1\">",
"      Insulin algorithm 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/60/20427\" title=\"table 2\">",
"      Insulin algorithm lispro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/21/19803\" title=\"table 3\">",
"      Insulin algorithm 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4233="Contraception counseling for obese women";
var content_f4_8_4233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contraception counseling for obese women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Alison Edelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Bliss Kaneshiro, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/8/4233/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/8/4233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of obesity is increasing in children, adolescents, and adults in developed countries worldwide. In the United States, it is estimated that more than one-third of adults are obese [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/1\">",
"     1",
"    </a>",
"    ]. The personal and societal costs of obesity are significant since obesity is associated with an increased risk of several medical disorders and pregnancy complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of safe and effective contraception by women not wishing to conceive is of the utmost importance for preventing unintended pregnancy. Because women with chronic conditions like obesity are at higher risk of pregnancy-related complications, proper contraceptive use and avoidance of unintended pregnancy are especially important in this population. In addition, some contraceptive methods offer noncontraceptive medical benefits, such as reduction in risk of endometrial and ovarian cancer and decreased menstrual bleeding. Nevertheless, one study reported that obese sexually active women were more likely to report contraceptive nonuse than normal weight women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/3\">",
"     3",
"    </a>",
"    ]. Of note, obesity is not significantly associated with sexual orientation, age at first intercourse, frequency of heterosexual intercourse, or the number of lifetime or current male partners [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Counseling obese women about their contraceptive options can be challenging. Historically, contraceptive research has excluded obese and overweight women from clinical trials resulting in a limited body of evidence regarding contraceptive effectiveness and safety in obese and overweight women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to explore all of the factors that can contribute to contraceptive failure, not just the effect of weight, since approximately one-half of all pregnancies are unintended and one-half of these occur in women using some form of contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/5\">",
"     5",
"    </a>",
"    ]. In large groups of women, the overall rate of contraceptive failure is related to the inherent effectiveness of the method, compliance, fecundity of the population, and sexual behavior (eg, rare versus frequent sexual intercourse). There is no evidence that obesity affects compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/6\">",
"     6",
"    </a>",
"    ] or frequency of sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/4\">",
"     4",
"    </a>",
"    ]. Obesity can affect fecundity, but the majority of obese women ovulate regularly. There is some evidence that, compared to normal weight women, the risk of contraceptive failure is higher in obese women using the contraceptive patch [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2,7\">",
"     2,7",
"    </a>",
"    ], combined oral contraceptive pills [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and contraceptive implants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/10\">",
"     10",
"    </a>",
"    ]; however, the magnitude of excess risk is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/11\">",
"     11",
"    </a>",
"    ]. However, data from the 2002 National Survey of Family Growth do not support an association between obesity and unintended pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/12\">",
"     12",
"    </a>",
"    ]. This makes it difficult to properly inform overweight and obese women of their risk of pregnancy when using hormonal methods.",
"   </p>",
"   <p>",
"    As a general guideline, the emotional aspects of unintended conception and the health risks of pregnancy should be weighed against the risks and disadvantages associated with a specific contraceptive method and the risk of contraceptive failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute of Health and World Health Organization classify weight as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underweight &mdash; Body mass index (BMI) &lt;18. 5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Normal weight &mdash; BMI &ge;18.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Overweight &mdash; BMI &ge;25.0 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Class I obesity &mdash; BMI = 30.0 to 34.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Class II obesity &mdash; BMI = 35.0 to 39.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Class III obesity &mdash; BMI &ge;40",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      This type of obesity is also referred to as severe or extreme obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOW OBESITY COULD REDUCE CONTRACEPTIVE EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many metabolic processes are affected by adiposity, and these changes in metabolism could potentially affect contraceptive efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/13\">",
"     13",
"    </a>",
"    ]. There is some evidence from human studies that oral contraceptive pharmacokinetics are altered in obese women, resulting in inadequate hypothalamic-pituitary-ovarian (HPO) suppression; but further study is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since changes in metabolism are more contingent upon adiposity than on body proportions (ie, body mass index [BMI]), weight is probably more relevant than BMI in determining variability in contraceptive efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/17\">",
"     17",
"    </a>",
"    ]. Higher weight correlates with an increased metabolic rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In particular, the clearance of hepatically metabolized drugs, such as contraceptive steroids, increases with increasing body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/18\">",
"     18",
"    </a>",
"    ]. Theoretically, the half life of these drugs might be shorter in obese women and serum levels might be insufficient to maintain a contraceptive effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, obese women have a larger circulating blood volume than normal weight women. This may cause significant dilution of the concentration of contraceptive steroids, thereby decreasing contraceptive efficacy. Furthermore, contraceptive steroids are absorbed by adipose tissue, so women with more adipose may have less steroid available to circulate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and route of hormone administration may affect these metabolic differences. As an example, in one study, oral contraceptives with ethinyl estradiol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    (LNG) demonstrated no differences in drug volume of distribution in obese women, but had a prolonged time to reach a steady state due to a longer LNG half-life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/14\">",
"     14",
"    </a>",
"    ]. On the other hand, a similar study showed no changes in hypothalamic ovarian suppression (follicular activity and hormonal measurements) between normal and obese women, but noted that the obese study subjects were less compliant about consistent OC use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/22\">",
"     22",
"    </a>",
"    ]. Both of these studies are limited in that pregnancy is not the main endpoint.",
"   </p>",
"   <p>",
"    Based on the potential effects of obesity on the pharmacokinetics of contraceptive steroids, it is tempting to simply recommend doubling the dose of contraceptive used by obese women. However, side effects and risks would also increase. As an example, a high dose of estrogen containing contraceptives would increase the risk of deep venous thrombosis and would be compounded by the risk already present for obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF CONTRACEPTIVES IN OBESE WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that combined oral contraceptive pills [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], the contraceptive patch [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2,7\">",
"     2,7",
"    </a>",
"    ], and contraceptive implants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/10\">",
"     10",
"    </a>",
"    ] are less effective in women of higher body weights. For other methods, there is either no evidence that efficacy differs by body weight or there are no studies examining the effect of body weight on efficacy since phase 2 and phase 3 trials have traditionally excluded obese women. The potentially higher failure rates associated with hormonal methods need to be weighed against the potentially high user failure rates associated with barrier methods: pregnancy rates probably remain lower than with barrier methods because improved adherence likely overrides the negative effects of obesity.",
"   </p>",
"   <p>",
"    Abnormalities in body weight and metabolism can adversely affect the reproductive system. Obesity is a known risk factor for reduced fertility (subfecundity) because of menstrual abnormalities, anovulation, polycystic ovarian disease, and insulin resistance. However, only a minority of obese women experience these problems; most obese women have normal fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methods which may be less effective",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether oral contraceptives are less effective in women of higher weight has not been clearly determined. The following is a summary of the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several studies have shown no association [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. As an example, a large cohort study of 17,032 women participating in the Oxford-Family Planning Association showed no association between weight and risk of unintended pregnancy in women using either progestin only pills or combined oral contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a retrospective cohort study of women in a health maintenance organization taking combined oral contraceptives (less than 35 mcg of ethinyl estradiol) reported those who weighed more than 70.5 kg had a higher risk of pregnancy than lighter women (RR 1.6, 95% CI 1.1-2.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/9\">",
"       9",
"      </a>",
"      ]. Another study using data from a health maintenance organization found that women with a body mass index (BMI) greater than 27.3",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      had an increased risk of pregnancy (OR 1.58, 95% CI 1.11-2.24) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/8\">",
"       8",
"      </a>",
"      ]. This risk was higher in women with BMI greater than 32.2",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (OR 1.72, 95% CI 1.04-2.82) and the association was stronger when data were adjusted for consistency of pill use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if future data show that oral contraceptives are less effective in obese women than in normal weight women, it is likely that their overall effectiveness would still remain high. Based on available evidence, the decreased efficacy of oral contraceptives in obese women would result in an additional two to four pregnancies per 100 woman-years of oral contraceptive use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/8\">",
"     8",
"    </a>",
"    ]. In our opinion, this does not necessitate advising obese women that their risk of contraceptive failure is significantly increased compared with normal weight women.",
"   </p>",
"   <p>",
"    Women of any weight who want to minimize their risk of pregnancy should choose a method with a low typical use failure rate, such as intrauterine contraception, given the overall typical use failure rate for combined oral contraceptive pills in the first year of use is 8 pregnancies per 100 women (",
"    <a class=\"graphic graphic_table graphicRef70218 \" href=\"UTD.htm?12/56/13197\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/29\">",
"     29",
"    </a>",
"    ]. Obese women can also consider using dual methods, such as combined oral contraceptive pills and condoms; this would decrease pregnancy risk, as well as the risk of acquiring sexually transmitted infections. For obese women who choose oral contraception, there is insufficient evidence for recommending a specific estrogen dose or for using a higher rather than a lower dose oral contraceptive pill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Contraceptive patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pooled analysis of three large studies examining the efficacy of the contraceptive patch suggested that the patch may be less effective in the subgroup of women with a body weight greater than 90 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/7\">",
"     7",
"    </a>",
"    ]. In this analysis, 5 of the 15 pregnancies in patch users occurred in the 83 women (3 percent of study subjects) who weighted 90 kg or more. The small number of pregnancies that occurred in this pooled analysis made it impossible to provide a good estimate of the excess risk of contraceptive failure in women weighing more than 90 kg. However, overall contraceptive efficacy is probably high in obese women because pharmacokinetic studies have estimated that there is only 10 to 20 percent variability in hormone levels due to body weight. There is normally this amount of variability in steroid levels between individuals.",
"   </p>",
"   <p>",
"    Of note, efficacy studies of the contraceptive patch included a higher proportion of overweight and obese women and a wider range of body weights than studies of other contraceptive methods. Indeed, most oral contraceptive studies excluded women with more than a 20 percent variation from ideal body weight, whereas studies of the oral contraceptive patch included women as much as 35 percent above their ideal body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Contraceptive implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the single rod",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    contraceptive implant (Implanon or Nexplanon, the only contraceptive implant in use in the United States), available data do not show any weight-related impairment in contraceptive efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, women more than 130 percent of their ideal body weight (BMI greater than 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    were excluded from initial trials of safety and efficacy. A subsequent prospective cohort study did not find a statistically significant difference in contraceptive failure rate between",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    etonogestrel implant users (n = 729) and normal weight etonogestrel implant users (n = 439) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/31\">",
"     31",
"    </a>",
"    ]. One unintended pregnancy occurred among 1377 women-years of implant use. The pregnancy occurred in an obese participant who had a BMI of 30.7 at enrollment. Although the study was not powered to detect small differences in failure rates in women of differing BMI, these results are reassuring. However, it should be noted that etonogestrel concentrations are 30 to 60 percent lower in obese women than in women of normal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contraceptive efficacy of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing six rod implant Norplant has been questioned in obese women, based on several large studies. Women using this implant who weighed more than 70 kg had a pregnancy rate five times higher than women weighing less than 50 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, it is important to note that the overall contraceptive efficacy of Norplant was high in women of the highest weight category: there were only 0.86 pregnancies per 100 woman-years over the seven years of Norplant use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have also been concerns with Jadelle, another",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing contraceptive implant which consists of two rods. In one study, levonorgestrel levels were inversely related to the ponderal index (another type of ratio of body weight to height), as well as weight [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/35\">",
"     35",
"    </a>",
"    ]. Over the seven years of the study, the mean serum drug concentration of women who weighed less than 50 kg at admission was about 1.8 times that of women who had weighed 70 kg or more at study initiation. However, levonorgestrel levels sufficient for effective contraception were maintained for the first five years of implant use for women of all weights. Sixteen percent of participants in this study weighed 70 kg or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28036443\">",
"    <span class=\"h3\">",
"     Contraceptive ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All trials assessing the effectiveness of the estrogen-progestin vaginal ring have been conducted in nonobese women. Since there are no data from use in obese women, the World Health Organization (WHO) and the Centers for Disease Control (CDC) elected to place the patch and ring forms of combined estrogen-progestin contraception in the same risk category. For obese women, they concluded that the advantages of using the method generally outweigh the theoretical or proven risks based on data that obesity is an independent risk factor for venous thrombosis (VTE) and case control studies that suggest this risk is additive in users of contraceptives involving estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'WHO and CDC medical eligibility criteria for contraceptive use'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A small study that compared obese and normal BMI ring users found that follicular development was minimal in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/39\">",
"     39",
"    </a>",
"    ]. Although reassuring, the study was conducted over only one cycle in a small group of women, thus efficacy could not be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effective methods with potential procedural challenges",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of impaired contraceptive efficacy for obese women who rely on either the copper intrauterine contraceptive device or the initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine contraceptive device, which releases levonorgestrel at a rate of 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (LNg20; total levonorgestrel content: 52 mg). A prospective cohort study found no statistically significant difference in the contraceptive failure rate during the first two to three years of use among IUD users who were of normal weight (n = 1584), overweight (n = 1149), or obese (n = 1467): the overall failure rate of less than 1 pregnancy per 100 woman years did not vary by BMI status [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial efficacy trial of a subsequent lower dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD, which releases levonorgestrel at a rate of 14",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (LNg14; total levonorgestrel content: 13.5 mg) included women 38 to 155 kg (mean 68.7 kg) and BMI 16 to 55",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (mean",
"    <span class=\"nowrap\">",
"     25.3kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    Lower efficacy in obese study participants was not reported.",
"   </p>",
"   <p>",
"    Visualizing the cervix and determining the size and direction of the uterus can be challenging in severely obese women during insertion of the device. Optimizing equipment by selecting a large speculum or removing the tip of a condom and placing it over the blades of the speculum can help with exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/2\">",
"     2",
"    </a>",
"    ]. In this setting, ultrasound may also be of assistance to guide insertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although sometimes difficult to insert, intrauterine contraception appears to be the best contraceptive option for obese women who have no contraindications to use of this method. The method is highly effective regardless of weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity is a risk factor for endometrial hyperplasia and endometrial cancer. Both the copper and LNg20 intrauterine contraceptives have been associated with a decrease in this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Surgical Sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In obese women, tubal sterilization procedures are more difficult and associated with longer operating times, more anesthetic and surgical complications, and prolonged hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hysteroscopic tubal occlusion (Essure&reg;) may be the safest surgical sterilization procedure for obese women because it can be done without general anesthesia and does not require entrance into the abdominal cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of hysteroscopy\", section on 'Sterile preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effective methods with potential user issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Depot medroxyprogesterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two studies addressing the contraceptive efficacy of depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    in obese women. A trial on the contraceptive efficacy of depot medroxyprogesterone acetate-SC included obese women and reported no pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/44\">",
"     44",
"    </a>",
"    ]. Another study compared the pharmacokinetics of depot medroxyprogesterone acetate-SC in Class I, II and III obese women with normal weight women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/45\">",
"     45",
"    </a>",
"    ]. Although estradiol levels fluctuated more frequently in obese women compared to normal weight women, the median medroxyprogesterone levels remained above the level needed to prevent ovulation.",
"   </p>",
"   <p>",
"    Of note, the persistence of ovulation suppression following discontinuation of depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    is related to weight. Women with lower body weights conceive sooner than women with higher body weights after discontinuing the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight gain is a concern for many women, particularly women who are already overweight or obese. Fear of weight gain is often cited as a reason women do not initiate or continue hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/46\">",
"     46",
"    </a>",
"    ]. Although randomized trials have not reported significant weight gain in depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    users [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], observational studies have reported certain groups of women may gain weight with depot medroxyprogesterone acetate use. Some of these studies have shown that overweight and obese adolescents gain more weight when using this method than when using oral contraceptives or no contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. A study in adult women found that normal and overweight women gained weight with depot medroxyprogesterone acetate use, whereas obese women did not [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, there is good evidence demonstrating that use of combined hormonal contraceptives, progestin only pills, intrauterine contraception, and contraceptive implants is not associated with weight gain or discontinuation of a contraceptive due to weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/30,54-57\">",
"     30,54-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Barrier methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barrier methods of contraception have fewer side effects than hormonal contraception and should be effective in obese women. However, no studies have evaluated the use of barrier methods in this subgroup of users.",
"   </p>",
"   <p>",
"    Condoms (male and female), the diaphragm, cervical cap, and contraceptive sponge are the most common forms of barrier contraception. However, these are event-based methods of contraception, which makes them more prone to user-related contraceptive failure. Because women with chronic conditions like obesity are at higher risk of pregnancy-related complications, proper contraceptive use and unintended pregnancy avoidance is especially important in this population. If a double barrier method is used (eg, condom and vaginal spermicide, diaphragm and condom), efficacy increases substantially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of contraception\", section on 'Barrier methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Postbariatric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The weight loss that accompanies bariatric surgery can result in more regular menses and an increase in fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Women who undergo restrictive bariatric procedures can safely and effectively use oral contraceptives. However, procedures causing malabsorption, such as biliopancreatic diversion or jejunoileal bypass or Roux-en-Y bypass, may theoretically interfere with the absorption of oral contraceptives, thus reducing their effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. For this reason, the American College of Obstetricians and Gynecologists (ACOG) suggests that women undergoing bariatric surgery with a significant malabsorption component who want to use hormonal contraception should preferentially consider non-oral delivery of the contraceptive hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/63\">",
"     63",
"    </a>",
"    ]. Non-oral hormonal contraceptives have been studied in only small numbers of obese patients, but appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonhormonal methods are an acceptable alternative.",
"   </p>",
"   <p>",
"    Of note, obese women planning to undergo surgery that involves prolonged immobilization should not use estrogen containing contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=see_link\">",
"     \"Fertility and pregnancy after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25188590\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although obesity is a risk factor for cardiovascular disease, obese women who use combined hormonal contraceptives do not appear to have a higher risk of myocardial infarction or stroke than obese nonusers; however, data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/67\">",
"     67",
"    </a>",
"    ]. The presence of additional risk factors for cardiovascular disease (eg, older age, some medical disorders) should be taken into account when counseling obese women about the risks of estrogen-progestin contraceptives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     WHO and CDC medical eligibility criteria for contraceptive use",
"    </span>",
"    &nbsp;&mdash;&nbsp;WHO and CDC Medical Eligibility Criteria for Contraceptive Use are good tools to assist practitioners in advising obese women and women with coexisting medical problems about contraceptive options [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    WHO defined obesity as body mass index (BMI) &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82680 \" href=\"UTD.htm?20/51/21311\">",
"     table 2",
"    </a>",
"    ). For obesity without coexistent medical problems, WHO categorizes intrauterine contraception, contraceptive implants, depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , and progestin-only pills as class 1, which means that there are no restrictions in the use of these methods for obese women. Estrogen containing contraception including combined oral contraceptive pills, the contraceptive patch, and the contraceptive ring are categorized as class 2, which means that the advantages of using the method generally outweigh the theoretical or proven risks. The class 2 rating is based on data that obesity is an independent risk factor for venous thrombosis (VTE) and case control studies suggest that this risk is additive in users of contraceptives involving estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The CDC came to similar conclusions (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Of note, the Faculty of Family Planning and Reproductive Health Care in the United Kingdom assigned women with BMI 35 to 39 and &ge;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    a class 3 and a class 4 rating, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/66\">",
"     66",
"    </a>",
"    ]; however, there is no consensus that this distinction is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/70\">",
"     70",
"    </a>",
"    ]. There is no safety information for women with BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of medical comorbidities, the degree to which age alone increases the risk of VTE is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .) However, age does increase the risk of comorbidities, such as cardiovascular disease, which are associated with VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, older obese women may have a higher risk of VTE and should be properly counseled about this risk. The American College of Obstetricians and Gynecologists concluded &ldquo;Because of the increased risk of venous thrombotic embolism, combination contraceptives should be used with caution in women older than 35 years who are obese&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/72\">",
"     72",
"    </a>",
"    ]. It is also important to remember that women continue to be fertile well past the age of 40, and obese women in this age group who become pregnant are at increased risk of pregnancy related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/8/4233/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As obese women are at an increased risk for a number of comorbidities, such as diabetes mellitus and hypertension, practitioners should consult the WHO and CDC Medical Eligibility Criteria (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ) when comorbidities are present. The complete WHO tables can be viewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of estrogen containing contraceptives, as well as contraindications to specific contraceptives, are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Counseling obese women about their contraceptive options can be challenging. Historically, contraceptive research has excluded obese and overweight women from clinical trials addressing efficacy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug metabolism, drug distribution in adipose tissue, and a dilutional effect could affect the half-life of hormonal contraceptives in obese women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'How obesity could reduce contraceptive efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When counseling patients, the risks of unintended conception and pregnancy should be weighed against the risks, advantages, and disadvantages associated with a particular contraceptive. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methods which may be less effective'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is some evidence that contraceptive failure occurs more often in obese women using oral contraceptives, the contraceptive patch, or contraceptive implants than in women of normal weight. Even if the risk of contraceptive failure is increased, the effectiveness probably remains relatively high. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methods which may be less effective'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For obesity without coexistent medical problems, the World Health Organization categorizes intrauterine contraception, contraceptive implants, depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , and progestin-only pills as class 1, which means that there are no restrictions in the use of these methods for obese women.",
"      <br/>",
"      <br/>",
"      Obesity is an independent risk factor for venous thrombosis (VTE) and this risk is increased in users of contraceptives involving estrogen. Estrogen containing contraception including combined oral contraceptive pills, the contraceptive patch, and the contraceptive ring are categorized as class 2, which means that the advantages of using the method generally outweigh the theoretical or proven risks. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'WHO and CDC medical eligibility criteria for contraceptive use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For obese women who want the most effective reversible method of contraception, we suggest intrauterine contraception over other methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Intrauterine contraception has a very low rate of failure (compared to barrier methods), is not associated with weight gain (compared to depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      ), and does not expose the woman to potential risks associated with estrogen containing contraceptives. (See Intrauterine contraception\" above).",
"     </li>",
"     <li>",
"      For obese women who desire a permanent method of contraception, we suggest hysteroscopic transcervical tubal occlusion over tubal ligation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Abdominal surgical procedures in obese women is associated with greater anesthesia risk, longer operating times, and prolonged hospitalization. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgical Sterilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bariatric surgery procedures causing malabsorption, such as biliopancreatic diversion or jejunoileal bypass, may interfere with the absorption of oral contraceptives, thus reducing their effectiveness. If hormonal contraception is used, we suggest non-oral hormonal contraceptives over oral hormonal contraceptives (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Postbariatric surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Adult obesity facts. file://www.cdc.gov/obesity/data/adult.html (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/2\">",
"      Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception 2005; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/3\">",
"      Chuang CH, Chase GA, Bensyl DM, Weisman CS. Contraceptive use by diabetic and obese women. Womens Health Issues 2005; 15:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/4\">",
"      Kaneshiro B, Jensen JT, Carlson NE, et al. Body mass index and sexual behavior. Obstet Gynecol 2008; 112:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/5\">",
"      Kost K, Singh S, Vaughan B, et al. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/6\">",
"      Society of Family Planning, Higginbotham S. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception 2009; 80:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/7\">",
"      Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/8\">",
"      Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/9\">",
"      Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002; 99:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/10\">",
"      Gu S, Sivin I, Du M, et al. Effectiveness of Norplant implants through seven years: a large-scale study in China. Contraception 1995; 52:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/11\">",
"      Trussell J, Schwarz EB, Guthrie K. Obesity and oral contraceptive pill failure. Contraception 2009; 79:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/12\">",
"      Kaneshiro B, Edelman A, Carlson N, et al. The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception 2008; 77:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/13\">",
"      Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010; 82:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/14\">",
"      Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/15\">",
"      Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/16\">",
"      Edelman AB, Cherala G, Munar MY, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception 2013; 87:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/17\">",
"      Owen OE, Kavle E, Owen RS, et al. A reappraisal of caloric requirements in healthy women. Am J Clin Nutr 1986; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/18\">",
"      Speerhas R. Drug metabolism in malnutrition and obesity: clinical concerns. Cleve Clin J Med 1995; 62:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/19\">",
"      Ravussin E, Burnand B, Schutz Y, J&eacute;quier E. Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects. Am J Clin Nutr 1982; 35:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/20\">",
"      Stadel BV, Sternthal PM, Schlesselman JJ, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 1980; 33:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/21\">",
"      Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab 1975; 41:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/22\">",
"      Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010; 116:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/23\">",
"      Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/24\">",
"      Nightingale AL, Lawrenson RA, Simpson EL, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/25\">",
"      Vessey M. Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 2001; 27:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/26\">",
"      Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/27\">",
"      Burkman RT, Fisher AC, Wan GJ, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/28\">",
"      McNicholas C, Zhao Q, Secura G, et al. Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstet Gynecol 2013; 121:585.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff L, Darney PD. A Clinical Guide For Contraception, 54th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/30\">",
"      Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/31\">",
"      Xu H, Wade JA, Peipert JF, et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/32\">",
"      Mornar S, Chan LN, Mistretta S, et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012; 207:110.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/33\">",
"      Gu SJ, Du MK, Zhang LD, et al. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet Gynecol 1994; 83:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/34\">",
"      Grubb GS, Moore D, Anderson NG. Pre-introductory clinical trials of Norplant implants: a comparison of seventeen countries' experience. Contraception 1995; 52:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/35\">",
"      Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001; 64:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/36\">",
"      Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/37\">",
"      Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/38\">",
"      Lidegaard &Oslash;, Edstr&ouml;m B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/39\">",
"      Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012; 207:39.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/40\">",
"      Chi IC, Wilkens L. Interval tubal sterilization in obese women--an assessment of risks. Am J Obstet Gynecol 1985; 152:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/41\">",
"      Chi IC, Wilkens LR, Reid SE. Prolonged hospital stay after laparoscopic sterilization. IPPF Med Bull 1984; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/42\">",
"      Chi I, Mumford SD, Laufe LE. Technical failures in tubal ring sterilization: Incidence, perceived reasons, outcome, and risk factors. Am J Obstet Gynecol 1980; 138:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/43\">",
"      Jamieson DJ, Hillis SD, Duerr A, et al. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 2000; 96:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/44\">",
"      Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/45\">",
"      Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/46\">",
"      Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/47\">",
"      Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998; 43:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/48\">",
"      Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001; 73:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/49\">",
"      Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006; 160:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/50\">",
"      Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond) 2005; 29:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/51\">",
"      Bonny AE, Britto MT, Huang B, et al. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol 2004; 17:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/52\">",
"      Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/53\">",
"      Pantoja M, Medeiros T, Baccarin MC, et al. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception 2010; 81:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/54\">",
"      Goldzieher JW, Moses LE, Averkin E, et al. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971; 22:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/55\">",
"      Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; :CD003987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/56\">",
"      Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/57\">",
"      Edelman A, Jensen JT, Bulechowsky M, Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod 2011; 26:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/58\">",
"      Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril 2009; 92:1501.",
"     </a>",
"    </li>",
"    <li>",
"     Gosman, GG. Reproductive health of women electing bariatric surgery. Fertil Steril 2009; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/60\">",
"      Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006; 16:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/61\">",
"      Gerrits EG, Ceulemans R, van Hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg 2003; 13:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/62\">",
"      Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987; 16:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/63\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol 2009; 113:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/64\">",
"      Ciangura C, Corigliano N, Basdevant A, et al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports. Contraception 2011; 84:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/65\">",
"      Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt) 2011; 20:533.",
"     </a>",
"    </li>",
"    <li>",
"     Medical Eligibility Criteria for Contraceptive Use (UK MEC 2005/2006), Faculty of Family Planning and Reproductive Health Care, London (2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/67\">",
"      Centers for Disease Control and Prevention (CDC). U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/topics/contraception/en/. (Accessed February 6, 2008).",
"    </li>",
"    <li>",
"     U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. file://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/70\">",
"      Trussell J, Guthrie KA, Schwarz EB. Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis. Contraception 2008; 77:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/71\">",
"      Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/72\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/8/4233/abstract/73\">",
"      Riphagen FE, Fortney JA, Koelb S. Contraception in women over forty. J Biosoc Sci 1988; 20:127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5470 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4233=[""].join("\n");
var outline_f4_8_4233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOW OBESITY COULD REDUCE CONTRACEPTIVE EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECTIVENESS OF CONTRACEPTIVES IN OBESE WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methods which may be less effective",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Contraceptive patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28036443\">",
"      - Contraceptive ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effective methods with potential procedural challenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Surgical Sterilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effective methods with potential user issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Depot medroxyprogesterone acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Barrier methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Postbariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25188590\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      WHO and CDC medical eligibility criteria for contraceptive use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5470\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5470|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13197\" title=\"table 1\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21311\" title=\"table 2\">",
"      WHO MEC Personal characteristics and reproductive history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 3\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=related_link\">",
"      Fertility and pregnancy after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=related_link\">",
"      Insertion and removal of an intrauterine contraceptive device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_8_4234="Resting myocardial perfusion imaging in ischemia";
var content_f4_8_4234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62918%7ECARD%2F80590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62918%7ECARD%2F80590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Acute rest technetium 99m sestamibi myocardial perfusion imaging in myocardial ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute rest myocardial perfusion imaging (upper rows) in a 38-year-old white man evaluated in the emergency department for atypical chest pain and a nondiagnostic electrocardiogram. There is an inferior defect which resolves on rest images obtained after stabilization with medical therapy (arrow). Gated SPECT (panel A) revealed hypokinesis in the area of the defect and allowed rapid estimation of the systolic function. The patient underwent emergent coronary angiography for recurrence of chest pain with subsequent ST elevation in the inferior leads, and was found to have an occluded right coronary artery. Successful coronary angioplasty was performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Heller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Normal acute rest technetium 99m sestamibi myocardial perfusion imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal acute myocardial perfusion scan was obtained on a 44-year-old female admitted with typical chest pain and nonspecific ECG abnormalities. Serial enzymes were negative for myocardial infarction and cardiac catheterization revealed normal coronary arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Heller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4234=[""].join("\n");
var outline_f4_8_4234=null;
var title_f4_8_4235="Indications for DLCO";
var content_f4_8_4235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for performing a diffusing capacity of the lungs for carbon monoxide (DLCO) test",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Differential diagnosis of airways obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening for mild (early) interstitial lung disease (ILD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Differential diagnosis of lung volume restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detection of pulmonary vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disability/impairment evaluations for ILD or COPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow-up for ILD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for oxygen therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ILD: interstitial lung disease; COPD: chronic obstructive pulmonary disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4235=[""].join("\n");
var outline_f4_8_4235=null;
var title_f4_8_4236="Clinically significant hemoglobin variants";
var content_f4_8_4236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinically significant hemoglobin variants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Altered physical/chemical properties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hb S (deoxyhemoglobin S polymerization): sickle syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hb C (crystallization): hemolytic anemia; microcytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unstable Hb variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital Heinz body hemolytic anemia (n = 135)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Variants with altered oxygen affinity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High affinity variants: erythrocytosis (n = 92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low affinity variants: anemia, cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        M-hemoglobins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methemoglobinemia, cyanosis (n = 9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Variants causing a thalassemic phenotype (n = 50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &beta;-thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hb Lepore (&delta;&beta;) fusion (n = 3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aberrant RNA processing (Hb E, Hb Knossos, Hb Malay)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperunstable globins (Hb Geneva, Hb Westdale, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &alpha;-thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chain termination mutants (Hb Constant Spring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperunstable variants (Hb Quong Sze)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic, and Clinical Aspects, WB Saunders, Philadelphia 1986. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4236=[""].join("\n");
var outline_f4_8_4236=null;
var title_f4_8_4237="Evaluation bronchiectasis 2";
var content_f4_8_4237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of bronchiectasis-2",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific examples/features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Immunodeficiency states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IgG deficiency",
"       </td>",
"       <td>",
"        Congenital (Bruton's type) agammaglobulinemia; selective deficiency of subclasses (IgG2, IgG4); acquired immune globulin deficiency; common variable hypogammaglobulinemia; Nezelof's syndrome; \"bare lymphocyte\" syndrome",
"       </td>",
"       <td>",
"        Quantitative immunoglobulin levels; immunoglobulin subclass levels; impaired response to immunization with pneumococcal vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IgA deficiency",
"       </td>",
"       <td>",
"        Selective IgA deficiency &plusmn; ataxia-telegiectasia syndrome",
"       </td>",
"       <td>",
"        Quantitative immunoglobulin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukocyte dysfunction",
"       </td>",
"       <td>",
"        Chronic granulomatous disease (NADPH oxidase dysfunction)",
"       </td>",
"       <td>",
"        Dihydrorhodamine 123 (DHR) oxidation test; nitroblue tetrazolium test; genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other rare humoral immunodeficiencies (CXCR4 mutation, CD40 deficiency, CD40 ligand deficiency, and others)",
"       </td>",
"       <td>",
"        WHIM; Hypergammaglobulinemia M",
"       </td>",
"       <td>",
"        Neutrophil count; quantitative immunoglobulin levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Abnormal secretion clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciliary defects of airway mucosa",
"       </td>",
"       <td>",
"        Kartagener's syndrome; ciliary dyskinesis",
"       </td>",
"       <td>",
"        Chest image showing situs inversus; bronchial biopsy; ciliary motility studies; electron microscopy of sperm or respiratory mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cystic fibrosis (mucoviscidosis)",
"       </td>",
"       <td>",
"        Typical early childhood syndrome; later presentation with predominantly sinopulmonary symptoms",
"       </td>",
"       <td>",
"        Sweat chloride; genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Young's syndrome",
"       </td>",
"       <td>",
"        Obstructive azoospermia with sinopulmonary infections",
"       </td>",
"       <td>",
"        Sperm count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Miscellaneous disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1 antitrypsin deficiency",
"       </td>",
"       <td>",
"        Absent or abnormal antitrypsin synthesis and function",
"       </td>",
"       <td>",
"        Alpha-1 antitrypsin level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent aspiration pneumonia",
"       </td>",
"       <td>",
"        Alcoholism; neurologic disorders; lipoid pneumonia",
"       </td>",
"       <td>",
"        History; chest imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatic&nbsp;disease",
"       </td>",
"       <td>",
"        Associated with rheumatoid arthritis and Sjogren's syndrome",
"       </td>",
"       <td>",
"        Rheumatoid factor; antiSSA/antiSSB; salivary gland MRI or biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease",
"       </td>",
"       <td>",
"        Crohn's disease; ulcerative colitis",
"       </td>",
"       <td>",
"        History; lower gastrointestinal endoscopy; imaging studies; colonic biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inhalation of toxic fumes and dusts",
"       </td>",
"       <td>",
"        Ammonia; nitrogen dioxide, or other irritant gases; smoke; talc; silicates",
"       </td>",
"       <td>",
"        Exposure history; chest imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic rejection following organ transplantation",
"       </td>",
"       <td>",
"        Bone marrow, lung and heart lung transplantation; associated with obliterative bronchiolitis",
"       </td>",
"       <td>",
"        History; PFT; chest CT imaging with inspiratory and expiratory views",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4237=[""].join("\n");
var outline_f4_8_4237=null;
var title_f4_8_4238="Contents: Hernia surgery";
var content_f4_8_4238=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hernia surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hernia surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41061\">",
"           Abdominal hernias in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41721\">",
"           Care of the umbilicus and management of umbilical disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28026\">",
"           Congenital diaphragmatic hernia in the neonate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42169\">",
"           Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/22/7527\">",
"           Hiatus hernia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/0/11268\">",
"           Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/49/26393\">",
"           Inguinal and femoral hernia repair: Laparoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9465\">",
"           Inguinal and femoral hernia repair: Open techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34632\">",
"           Operative management of recurrent inguinal hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43801\">",
"           Overview of abdominal hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/20/29000\">",
"           Overview of treatment for inguinal and femoral hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/43/19128\">",
"           Paraesophageal hernia: Clinical features and surgical repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24151\">",
"           Parastomal hernia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/34/32294\">",
"           Principles of component separation technique for complex abdominal wall defects and hernias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/57/20373\">",
"           Sports-related groin pain or 'sports hernia'",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43239\">",
"           Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B94C649B84-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_8_4238=[""].join("\n");
var outline_f4_8_4238=null;
var title_f4_8_4239="TEE abnormalities stroke risk";
var content_f4_8_4239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial abnormalities and complex aortic plaque correlate with the risk of thromboembolism in atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 437px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation of clinical risk for thromboembolism (TE) and transesophageal echocardiographic (TEE) findings in 786 patients with atrial fibrillation. Patients were deemed to be at high risk if they one or more of the following clinical features: prior TE, women &gt;75 years of age, systolic blood pressure &gt;160 mmHg, and heart failure or poor left ventricular function. Patients with none of these features were either at low risk or, if they had a history of hypertension, moderate risk. Panel A: There was an increasing incidence of a left atrial appendage (LAA) abnormality (thrombus, dense spontaneous echo contrast, or flow velocity &le;20 cm/s) or a complex aortic plaque risk with increasing clinical risk of TE. Panel B: The frequency of LAA abnormalities and complex aortic plaque in patients with a single high risk factor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Zabalgoitia M, Halperin JL, Pearce LA, et al. for the Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31:1622.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_8_4239=[""].join("\n");
var outline_f4_8_4239=null;
